Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost and cost-effectiveness of Mohs micrographic surgery versus conventional excision for nonmelanoma skin cancer: A scoping review.

JAAD international·2026
Same author

Evaluating Large Language Models for Melanocytic Lesion Pathology Report Interpretation.

Journal of cutaneous pathology·2026
Same author

Topical 5-fluorouracil versus photodynamic therapy: Differential impact on epidermal clonal mutations in early UV-induced skin carcinogenesis.

The Journal of investigative dermatology·2026
Same author

Dose‑dependent association of smoking exposure with HDL subfraction cholesterol content.

Scientific reports·2026
Same author

Evaluation of multimodal large language models for psoriasis diagnosis, severity grading, and treatment recommendations from clinical photographs: ChatGPT shows superior performance compared to other large language models.

Frontiers in medicine·2026
Same author

Lipid clinics worldwide: harmonization and guidance on how to optimally organize and fund. European Atherosclerosis Society consensus statement across 55 countries and more than 500 lipid clinics.

Atherosclerosis·2026

Related Experiment Video

Updated: May 9, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Persistence with statin therapy in Hungary.

Zoltan Kiss1, Laszlo Nagy, Istvan Reiber

  • 1MULTI GAP Study Group, Budapest, Hungary.

Archives of Medical Science : AMS
|July 13, 2013
PubMed
Summary

Cardiovascular patients in Hungary show low persistence with lipid-lowering drugs like statins. This poor adherence may limit the effectiveness of these crucial therapies.

Keywords:
Hungaryadherenceezetimibepersistencestatins

Related Experiment Videos

Last Updated: May 9, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

  • Cardiovascular Medicine
  • Pharmacoeconomics
  • Public Health

Background:

  • Lipid-lowering drug persistence in Hungarian cardiovascular patients remains unexamined.
  • This study aims to assess adherence rates and compare them internationally.

Purpose of the Study:

  • To determine the persistence rate of Hungarian hyperlipidemia patients on lipid-lowering agents.
  • To compare these rates with international data.

Main Methods:

  • Retrospective analysis of the National Health Insurance Fund database.
  • Inclusion of patients initiating statin or ezetimibe therapy between 2007 and 2009.
  • Evaluation of persistence via median duration, 6- and 12-month adherence percentages, and Kaplan-Meier plots.

Main Results:

  • Statin therapy persistence was 46% at 1 month, decreasing to 20.1% at 12 months.
  • Higher persistence observed for therapy initiated in 2008 versus 2007, and in older patients.
  • Combination ezetimibe-statin therapy demonstrated greater persistence than monotherapy.

Conclusions:

  • Lipid-lowering drug persistence in Hungary is notably low compared to other nations.
  • Suboptimal adherence may diminish the clinical advantages of long-term statin use.